Objective: This study aims to determine whether long-term isoflavone soy protein (ISP) supplementation affects endometrial thickness and rates of endometrial hyperplasia and cancer in postmenopausal women.
B ecause of concerns with traditional estrogen preparations for postmenopausal hormone therapy (HT), an increasing number of women in the United States are turning to alternative therapies such as phytoestrogens, which are nonsteroidal compounds contained in plants, fruits, and vegetables. 1, 2 One type of phytoestrogenVisoflavonesVis structurally similar to 17A-estradiol. Isoflavones therefore possess selective estrogen receptor modulator (SERM)Ylike activity, with varying estrogenic and antiestrogenic effects, depending on the receptor characteristics of the target tissue. 3 Although a high percentage of women use isoflavone soy protein (ISP) supplementation as an alternative to HT to help manage the effects of menopause, 4 research on the efficacy of ISP in this context has yielded conflicting results. The possibility that ISP has biological activity similar to estrogen, with concordant benefits and risks, has been studied with respect to vasomotor symptoms, 5, 6 bone, 7<11 heart disease, 12, 13 atherosclerosis, 14<16 and breast cancer. 17 The effect of ISP supplementation on the endometrium remains unclear.
A pilot study of phytoestrogen supplementation during a 6-month period among 27 participants demonstrated no effect on endometrial histology, 18 whereas a randomized controlled trial among 376 women suggested that 5-year phytoestrogen supplementation is associated with increased rates of endometrial hyperplasia. 19 The objective of the current study was to determine whether long-term ISP supplementation affects endometrial thickness and the rates of endometrial hyperplasia and cancer in postmenopausal women in a randomized controlled setting.
METHODS
The Women_s Isoflavone Soy Health trial was a randomized, double-blind, placebo-controlled trial conducted from April 2004 to March 2009. Three hundred fifty postmenopausal women aged 45 to 92 years were randomly assigned in a 1:1 ratio to daily soy protein 25 g or daily total milk proteinY matched placebo for a 3-year period.
The primary trial outcome was progression of subclinical atherosclerosis, assessed by the rate of change in the right distal common carotid artery intima-media thickness (CIMT). Primary trial endpoint data are published elsewhere. 20 Secondary endpoints were safety of ISP supplementation, including endometrial safety. Participants with a surgically absent uterus (n = 75) and participants with incomplete ultrasound surveillance of the endometrium during the trial (n = 51) were excluded from this analysis, resulting in a final study population of 224 participants.
The 25-g soy protein contained 91 mg of aglycon equivalents of naturally occurring isoflavones and their glycosides (154 mg of total isoflavone conjugates plus aglycons): genistein, 52 mg of aglycon equivalents (88 mg in total); daidzein, 36 mg of aglycon equivalents (61 mg in total); glycitein, 3 mg of aglycon equivalents (5 mg in total). The milk proteinYmatched placebo contained no isoflavones.
Randomization occurred within two strata of CIMT (G0.75 and Q0.75 mm). Within each stratum, blocked randomization was implemented with a masked block size. Randomization lists from a computerized random number generator (SAS statistical software) were prepared before trial initiation by the trial statistician. For each stratum, the randomization list included the product identification number and the treatment code (active or placebo). Blinded study product was prepared based on the randomization list. Upon determination of the trial eligibility of a given participant, the clinic staff pulled the next study product in sequence from the appropriate stratum and recorded the product identification number. The statistician monitored the fidelity of the randomization process. Participants, investigators, staff, imaging specialists, and data monitors were masked to treatment assignment. 20 The placebo and active treatments were taken in two evenly divided doses daily, delivered in either beverage powder food packs or food bars to provide variety and to maintain compliance. ISP and placebo products were prepared without charge by Solae LLC (St Louis, MO) and were identical in taste and appearance.
Trial inclusion criteria were the absence of vaginal bleeding for at least 1 year and a serum estradiol level lower than 20 pg/mL. Exclusion criteria were as follows: clinical signs, symptoms, or personal history of cardiovascular disease; diabetes mellitus or fasting serum glucose level higher than 126 mg/dL; fasting triglycerides level higher than 500 mg/dL; systolic blood pressure of 160 mm Hg or higher and/or diastolic blood pressure of 110 mm Hg or higher; untreated thyroid disease; serum creatinine level higher than 2 mg/dL; life-threatening illness with a prognosis of less than 5 years; alcohol intake of more than five drinks per day or substance abuse; use of postmenopausal HT; and soy, nut, or related food allergies.
Endometrial echocomplex (EEC) was measured by transvaginal ultrasound at baseline, 18 months of follow-up, and 30 months of follow-up, as well as at 36 months of follow-up in some participants. All EEC measurements were performed by the same physician (D.S.). Participants with an EEC higher than 5 mm and those with vaginal bleeding underwent endometrial biopsies. Endometrial biopsies were performed using suction pipettes. Endometrial biopsies were fixed in 10% neutral buffered formalin, routinely processed, and paraffin-embedded. Serial 5-Km sections were stained with H&E and examined under a light microscope by a gynecological pathologist (J.C.F.). Compliance with ISP supplementation was confirmed by plasma and urine isoflavone measurements. The University of Southern California Institutional Review Board approved the study protocol. All participants provided a written informed consent form.
Statistical analysis
All were intent-to-treat analyses, wherein participants were analyzed according to their randomized intervention. Treatment group comparisons on demographic and other baseline characteristics used W 2 tests for categorical variables and t tests for continuous variables. For each participant, the change in the EEC from baseline was computed at each EEC follow-up visit. Baseline EEC and baseline and on-trial blood levels of genistein, daidzein, and glycitein were compared between treatment groups using Wilcoxon rank sum tests. Because of multiple EEC measurements within participants during the trial, treatment groups were compared on the mean EEC change from baseline using generalized estimating equations, specifying an identity link and an exchangeable correlation structure among repeated measurements within each participant. A covariate specifying the randomization stratification factor of baseline CIMT was included in the generalized estimating equation model. Treatment group comparisons on the incidences of endometrial sampling, endometrial hyperplasia, and endometrial cancer used Fisher_s exact test. All statistical analyses used SAS version 9.2 (SAS Inc, Cary, NC). Statistical testing was conducted at a twosided 0.05 significance level.
RESULTS
A total of 666 visits among 224 participants were evaluated. The baseline characteristics between women randomized to placebo (n = 103) and women randomized to ISP (n = 121) were similar; treatment groups did not differ in age, body mass index, smoking status, past HT use, years since menopause, ethnic background, and education level ( Table 1) .
Baseline levels of plasma genistein, daidzein, and glycitein concentrations did not differ between treatment groups (all P 9 0.05; Table 2 ). During the study, the mean plasma concentrations of genistein, daidzein, and glycitein were statistically significantly higher in the ISP group than in the placebo group (P G 0.001; Table 2 ), suggesting compliance with the ISP supplements in the intervention group. Compliance was also assessed by package and bar count and found to be higher than 85% among both placebo-treated and ISP-treated participants 20 (data not shown).
The median baseline EEC in the placebo and ISP groups was 2.5 and 2.4 mm, respectively. The EEC decreased by a mean of 0.95 and 0.98 mm, respectively (Table 3) . Neither baseline EEC measurements nor changes in the EEC during the trial period were statistically significantly different between treatment groups (P 9 0.8).
Of the 103 placebo-treated participants, 7 (6.8%) underwent endometrial biopsy; 6 (85.7%) of these biopsies were benign. The indication for endometrial sampling was postmenopausal vaginal bleeding in three of the seven cases and asymptomatic endometrial thickening (EEC 95 mm) in the other four cases. Of the 121 participants in the soy group, 9 (7.4%) underwent endometrial biopsy. The indication for endometrial sampling was postmenopausal vaginal bleeding in three of the nine cases and asymptomatic endometrial thickening in the other six cases. The results were benign in all nine cases (100%; Table 4 ). There were no statistically significant differences in the incidences of endometrial sampling between groups (P = 0.37) and in the rates of the pathology diagnoses Bbenign, not otherwise specified,[ Batrophic,[ and Bproliferative.[ One woman in the placebo group was diagnosed with complex endometrial hyperplasia with atypia and underwent hysterectomy; the pathology result from this surgical operation indicated stage IB endometrial cancer. Although the rate of hyperplasia/malignancy was higher in the placebo group (n = 1/7; 14.3%) than in the ISP group (n = 0; 0%), the difference was not statistically significant (P = 0.48).
DISCUSSION
More and more postmenopausal women in the United States who are concerned about the perceived risks of conventional HT ingest ISP through food sources and supplements as an alternative therapy for menopausal symptoms. 4 Although research on the efficacy of these compounds with SERM-like activity on a variety of menopausal symptoms is conflicting, 5<17 the clinical reality is that an increasing number of postmenopausal women are using ISP, necessitating careful documentation of its safety. Previous studies on the effect of ISP on the endometrium have yielded conflicting results. A pilot study by Balk et al 18 in 2002 demonstrated no effect of phytoestrogen supplementation on endometrial histology but was limited by a small number of participants (27 participants randomized; 19 completed the study) and a treatment period of only 6 months. A larger 5-year study (376 women randomized; 298 completed the study) by Unfer et al 19 in 2004 found increased rates of endometrial hyperplasia. In their study, no cases of hyperplasia were observed in the placebo group, whereas 6 of 154 women (3.8%) in the ISP group developed hyperplasia at the end of the 5-year follow-up period. However, most of these cases were simple hyperplasia (5/6, 83.3%), with only one case of complex hyperplasia without atypia in the entire study population. In addition, the authors did not report on symptoms of postmenopausal bleeding or ultrasound monitoring of the EEC, and instead performed universal biopsies on all participants, making the study less clinically applicable.
Our study is the first study to assess the effect of long-term ISP supplementation on endometrial thickness and the rates of endometrial hyperplasia and cancer in a population of postmenopausal women who were closely monitored by ultrasound and biopsied according to currently used clinical criteria. All EEC measurements were performed by the same physician (D.S.), who has extensive gynecological ultrasound experience. It has previously been shown that there is an excellent correlation between intraobserver and interobserver measurements of endometrial stripe thickness. 21 We observed that 3-year ISP supplementation had no effect on endometrial thickness or on the rates of endometrial hyperplasia and cancer in postmenopausal women. In fact, the only case of endometrial hyperplasia/cancer occurred in the placebo group.
With its structural similarity to 17A-estradiol and with its SERM-like activity, ISP has been found to predominantly act on estrogen receptor A at the molecular level. 22 The main estrogen receptor in the endometrium and the main mediator of endometrial hyperplasia and cancer risk is estrogen receptor >. 23 This may explain our finding on the endometrial safety of 3-year ISP supplementation.
The exclusion criteria for the study included certain comorbid conditions such as hypertension, diabetes, and cardiovascular disease. The mean body mass index was within the overweightVbut not obeseVrange, and the study population included few smokers. The effects of ISP supplementation on women with multiple risk factors for carcinoma of the endometrium are unclear. In average-risk populations of postmenopausal women who are taking no estrogens or very-low-dose unopposed estrogen therapy, studies have shown minimal endometrial proliferation with low incidences of endometrial hyperplasia. 24<27 It is therefore conceivable that our study was underpowered to detect a small difference in the rates of endometrial hyperplasia. This should be taken into account when interpreting our results, and counseling of postmenopausal women should be individualized. Our findings need to be confirmed by larger-scale clinical trials and more basic research on the effects of ISP on the endometrium.
CONCLUSIONS
Three-year ISP supplementation has no effect on endometrial thickness or on the rates of endometrial hyperplasia and cancer in postmenopausal women. Adjusted for randomization stratum. Treatment groups compared using generalized estimating equations with identity link function and exchangeable correlation structure.
